// App-Quantinova.ai

4514 : A randomized phase II study of OGX-427 plus prednisone (P) versus P alone in patients (pts) with metastatic castration resistant prostate cancer (CRPC).

Researchers

Presenter

  • Kim N. Chi

Principal Investigators

  • Sebastien J. Hotte

  • Susan Ellard

  • Joel Roger Gingerich

  • Anthony Michael Joshua

  • Evan Y. Yu

  • Martin Edwin Gleave

Medical Centers

  • Princess Margaret Hospital, Toronto, ON, Canada

  • Cancer Centre for Southern Interior, Kelowna, BC, Canada

  • Fred Hutchinson Cancer Resaerch Center, Seattle, WA

  • Faculty of Medicine, University of Manitoba, Winnipeg, MB, Canada

  • Vancouver Prostate Centre, Vancouver, BC, Canada

  • British Columbia Cancer Agency, Vancouver, BC, Canada

  • Juravinski Cancer Centre, Burlington, ON, Canada

Locations

  • United States

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Metastatic castration-resistant prostate cancer

Biomarkers

  • Circulating tumor cells

  • Prostate specific antigen

Drug/Treatment

  • Prednisone

  • Apatorsen

Outcome

  • N/A

Study Design

  • randomized

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved